Abstract
The molecular mechanisms enabling cancer cells to survive loss-of-adhesion-induced apoptosis in the early phases of metastasis remain largely obscure. Interestingly, the overexpression of tissue factor (TF) on tumor cells is associated with successful metastasis and it has now become clear that coagulation factor VIIa (FVIIa), the natural binding partner of TF induces signal transduction in TF-expressing cells. Hence, we investigated the effects of FVIIa–TF interaction on cell survival. We observed that FVIIa, at physiologically relevant concentrations, inhibits cell death and caspase-3 activation induced by serum deprivation and loss of adhesion (lack of integrin signaling) in TF-overexpressing cells, but not in non-TF-expressing cells. This FVIIa effect was not dependent on the formation of the downstream coagulation products FXa or thrombin and was inhibited using an active site-blocked form of FVIIa (FVIIai). FVIIa incubation resulted in the prolonged activation of both the phosphatidylinositide-3-(OH) kinase and p42/p44 MAP kinase pathways, and studies employing pharmacological inhibitors revealed that both the pathways are required for FVIIa-induced cell survival and inhibition of caspase-3 activity. Finally, TF:FVIIa-induced FXa generation dramatically increased cell survival. We propose that FVIIa-induced cell survival may explain why overexpression of TF is associated with successful metastasis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bergmann A, Agapite J, McCall K and Steller H . (1998). Cell, 95, 331–341.
Camerer E, Gjernes E, Wiiger M, Pringle S and Prydz H . (2000a). J. Biol. Chem., 275, 6580–6585.
Camerer E, Huang W and Coughlin SR . (2000b). Proc. Natl. Acad. Sci. USA, 97, 5255–5260.
Camerer E, Røttingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG and Prydz H . (1999. J. Biol. Chem., 274, 32225–32233.
Guadagno TM and Assoian RK . (1991). J. Cell Biol., 115, 1419–1425.
Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T and Ushio Y . (1996). Cancer, 77, 1877–1883.
Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN and Hay N . (1997). Genes Dev., 11, 701–713.
Kulik G, Klippel A and Weber MJ . (1997). Mol. Cell. Biol., 17, 1595–1606.
Kurada P and White K . (1998). Cell, 95, 319–329.
Mueller BM, Reisfeld RA, Edgington TS and Ruf W . (1992). Proc. Natl. Acad. Sci. USA, 89, 11832–11836.
Mueller BM and Ruf W . (1998). J. Clin. Invest., 101, 1372–1378.
Mosmann TJ . (1983). Immunol. Methods, 65, 55–63.
Pendurthi UR, Allen KE, Ezban M and Rao LV . (2000). J. Biol. Chem., 275, 14632–14641.
Poulsen LK, Jacobsen N, Sørensen BB, Bergenhem N, Kelly JD, Foster DC, Thastrup O, Ezban M and Petersen LC . (1998). J. Biol. Chem., 273, 6228–6232.
Riewald M and Ruf W . (2001). Proc. Natl. Acad. Sci. USA, 98, 7742–7747.
Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR . (1990). J. Natl. Cancer Inst., 82, 1113–1118.
Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S and Imamura M . (2000). Cancer, 88, 295–301.
Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S and Suzuki H . (1998). Thromb. Haemost., 80, 894–898.
Sørensen BB, Freskgård PO, Nielsen LS, Rao LV, Ezban M and Petersen LC . (1999). J. Biol. Chem., 274, 21349–21354.
Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K, Okamoto K, Itoh H and Otsuki M . (2001). J. Gastroenterol., 36, 848–850.
Versteeg HH, Bresser HL, Spek CA, Richel DJ, Van Deventer SJ and Peppelenbosch MP . (2003). J. Thromb. Haemost., 1, 1012–1018.
Versteeg HH, Hoedemaeker I, Diks SH, Stam JC, Spaargaren M, Van Bergen en Henegouwen PM, Van Deventer SJ and Peppelenbosch MP . (2000). J. Biol. Chem., 275, 28750–28756.
Versteeg HH, Peppelenbosch MP and Spek CA . (2001). Thromb. Haemost., 86, 1353–1359.
Versteeg HH, Sørensen BB, Slofstra SH, Van den Brande JH, Stam JC, van Bergen en Henegouwen PM, Richel DJ, Petersen LC and Peppelenbosch MP . (2002). J. Biol. Chem., 277, 27065–27072.
Vrana J, Stang M, Grande JP and Getz MJ . (1996). Cancer Res., 56, 5063–5070.
Wang X, Gjernes E and Prydz H . (2002). J. Biol. Chem., 277, 23620–23626.
Acknowledgements
We thank Dr Lars C Petersen for the generous gift of the BHKTF cells. HHV was supported by an Ambrosius Fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Versteeg, H., Arnold Spek, C., Richel, D. et al. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23, 410–417 (2004). https://doi.org/10.1038/sj.onc.1207066
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207066
Keywords
This article is cited by
-
Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer
Biomarker Research (2023)
-
Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer
Scientific Reports (2023)
-
Identification of metabolism-related genes for predicting peritoneal metastasis in patients with gastric cancer
BMC Genomic Data (2022)
-
Implications of venous thromboembolism GWASÂ reported genetic makeup in the clinical outcome of ovarian cancer patients
The Pharmacogenomics Journal (2021)
-
Beyond thrombosis: the impact of tissue factor signaling in cancer
Journal of Hematology & Oncology (2020)